INDV
Indivior Pharmaceuticals, Inc.
35.50$
-1.9%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.9% | 71.7% | 54.8% | 56.3% | 54.6% | 63.6% | 64.2% | 65.5% | 65.1% | 54.2% | 55.7% | 58.8% | |
| 32.9% | 17.9% | 17.1% | 19.7% | 19.7% | 24.2% | 27.1% | 35.1% | 31.4% | 16.2% | 14.6% | 18.0% | |
| 39.0% | 23.2% | 22.7% | 24.7% | 21.7% | 24.3% | 27.1% | 35.1% | 31.4% | 16.2% | 14.6% | 18.0% | |
| 14.1% | 14.4% | 17.1% | 16.9% | 17.1% | 19.3% | 17.7% | 16.5% | 19.2% | 21.2% | 23.8% | 23.3% | |
| 7.7% | 7.6% | 11.2% | 11.1% | 12.2% | 13.5% | 11.9% | 10.3% | 11.1% | 12.7% | 12.7% | 12.2% | |
| – | 0.3% | 0.1% | 0.1% | 0.1% | 0.2% | – | – | – | 0.2% | 0.2% | – | |
| 11.8% | 0.7% | 15.7% | 14.1% | 12.8% | 0.4% | 0.5% | 0.5% | 0.1% | 0.2% | 0.2% | 0.2% | |
| 101.3% | 110.8% | 99.3% | 107.9% | 111.4% | 126.4% | 120.8% | 117.8% | 114.6% | 108.1% | 112.0% | 116.9% | |
| 66.9% | 73.1% | 59.3% | 65.9% | 65.7% | 71.2% | 73.1% | 72.7% | 68.1% | 75.9% | 65.1% | 70.4% | |
| 0.6% | 0.7% | 0.8% | 0.8% | 1.0% | 2.1% | 2.1% | 2.0% | 2.0% | 3.2% | 0.8% | 0.7% | |
| 3.8% | 2.2% | 2.8% | 3.0% | 3.4% | 4.8% | 13.3% | 3.4% | 2.9% | 4.0% | 2.9% | 2.4% | |
| 12.7% | 13.4% | 16.2% | 15.3% | 16.1% | 23.9% | 22.6% | 21.2% | 21.5% | 24.1% | 40.6% | 39.5% | |
| -1.3% | -10.8% | 0.7% | -7.9% | -11.4% | -26.4% | -20.8% | -17.8% | -14.6% | -8.1% | -12.0% | -16.9% | |
| 66.6% | -16.7% | 86.4% | 73.2% | 73.1% | -34.4% | -29.5% | -26.7% | -24.4% | -20.2% | -23.4% | -27.1% | |
| 7.4% | 8.0% | 9.6% | 8.8% | 9.1% | 9.7% | 9.0% | 8.5% | 9.1% | 10.4% | 10.8% | 10.5% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.